Try
Crinetics Pharmaceuticals Inc. Common Stock
CRNXUnited States
33 filed reports · 418 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
33 reports · Jun 2018 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 25 | 3,718 | Jun 2018 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 8 | 3,101 | Dec 2018 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 3, 2026 | 402 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 7, 2026 | 244 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 26, 2026 | 827 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 6, 2025 | 240 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 7, 2025 | 191 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 8, 2025 | 204 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Feb 27, 2025 | 511 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 12, 2024 | 168 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 8, 2024 | 162 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 9, 2024 | 158 | Open |
| FY2023 | 10-K | Dec 31, 2023 | Feb 28, 2024 | 379 | Open |
| FY2023 Q3 | 10-Q | Sep 30, 2023 | Nov 7, 2023 | 158 | Open |
Financial data
418 concepts · 6,819 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial400 concepts · 6,646 facts · Dec 2016 to Jul 2026
- Cash cash equivalents restricted cash and restricted cash equivalents48 · Dec 2016 to Jun 2026
- Net income loss48 · Dec 2016 to Jun 2026
- Research and development expense48 · Dec 2016 to Jun 2026
- Investment income interest47 · Dec 2016 to Jun 2026
- Nonoperating income expense47 · Dec 2016 to Jun 2026
- Operating income loss47 · Dec 2016 to Jun 2026
- Revenue47 · Dec 2016 to Jun 2026
- Share based compensation47 · Dec 2016 to Jun 2026
- Allocated share based compensation expense46 · Dec 2016 to Jun 2026
- Depreciation and amortization46 · Dec 2016 to Jun 2026
- General and administrative expense (US GAAP)46 · Dec 2016 to Jun 2026
- Increase decrease in prepaid deferred expense and other assets46 · Dec 2016 to Jun 2026
- Net cash provided by used in financing activities46 · Dec 2016 to Jun 2026
- Net cash provided by used in investing activities46 · Dec 2016 to Jun 2026
- Net cash provided by used in operating activities46 · Dec 2016 to Jun 2026
- Payments to acquire property plant and equipment46 · Dec 2016 to Jun 2026
- Stockholders equity (US GAAP)46 · Dec 2016 to Jun 2026
- Common stock shares issued45 · Dec 2017 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value44 · Dec 2016 to Jun 2026
- Common stock par or stated value per share44 · Dec 2017 to Jun 2026
- Comprehensive income net of tax44 · Dec 2016 to Jun 2026
- Increase decrease in accounts payable and accrued liabilities44 · Dec 2016 to Jun 2026
- Operating expenses (US GAAP)44 · Dec 2016 to Sep 2025
- Assets43 · Dec 2017 to Jun 2026
Segment17 concepts · 159 facts · Dec 2023 to Jun 2026
- Revenue25 · Dec 2023 to Jun 2026
- Atumelnant11 · Dec 2023 to Jun 2026
- Net income loss11 · Dec 2023 to Jun 2026
- Nonoperating income expense11 · Dec 2023 to Jun 2026
- Other research and development expense11 · Dec 2023 to Jun 2026
- Paltusotine11 · Dec 2023 to Jun 2026
- Reportable Segment11 · Dec 2023 to Jun 2026
- Research and development expense11 · Dec 2023 to Jun 2026
- Research and development stock-based compensation11 · Dec 2023 to Jun 2026
- Selling general and administrative expense11 · Dec 2023 to Jun 2026
- Cost of revenue (US GAAP)7 · Dec 2023 to Jun 2026
- External selling, general and administrative expenses7 · Dec 2023 to Jun 2026
- Selling, general and administrative stock-based compensation7 · Dec 2023 to Jun 2026
- Early research and development programs6 · Sep 2024 to Jun 2026
- Income loss from equity method investments3 · Dec 2023 to Dec 2025
- Income tax expense benefit3 · Dec 2023 to Dec 2025
- Equity method investment realized gain loss on disposal2 · Sep 2024 to Sep 2025
Product1 concepts · 14 facts · Dec 2023 to Jun 2026
- Revenue14 · Dec 2023 to Jun 2026
Segments
173 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments1 member · 159 facts
- Reportable159 · Dec 2023 to Jun 2026
Product or service2 members · 14 facts
- License And Service7 · Dec 2023 to Jun 2026
- Product7 · Dec 2023 to Jun 2026
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Earnings-release commentary116 claims from 10 reports · Sep 2024 to Jun 2026
- Management discussion (MD&A) commentary185 claims from 8 reports · Sep 2024 to Jun 2026
- Risk-factor changes16 claims from 1 reports · Dec 2025
- Risk factors149 risks from 2 annual reports · 2024 to 2025
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.